HUALAN BIOLOGICAL ENGINEERING INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.54 CNY | -2.63% |
|
-2.06% | -16.22% |
| Sales 2024 * | 6.26B 863M | Sales 2025 * | 7.2B 993M | Capitalization | 33.91B 4.68B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.92B 265M | Net income 2025 * | 2.03B 280M | EV / Sales 2024 * | 5.04 x |
| Net cash position 2024 * | 2.39B 330M | Net cash position 2025 * | 2.48B 342M | EV / Sales 2025 * | 4.37 x |
| P/E ratio 2024 * |
17.7
x | P/E ratio 2025 * |
16.7
x | Employees | 3,709 |
| Yield 2024 * |
1.13% | Yield 2025 * |
2.06% | Free-Float | 52.07% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.63% | ||
| 1 week | -2.06% | ||
| Current month | -8.08% | ||
| 1 month | -5.17% | ||
| 3 months | -2.27% | ||
| 6 months | -13.93% | ||
| Current year | -16.22% |
1 week
17.90
19.41
1 month
17.9020.45
Current year
16.5122.27
1 year
16.5124.55
3 years
15.0145.29
5 years
15.0176.00
10 years
7.6076.00
| Managers | Title | Age | Since |
|---|---|---|---|
Bei Fan
CEO | Chief Executive Officer | 52 | 92-03-29 |
Jun Min Xie
DFI | Director of Finance/CFO | 56 | 10-09-30 |
Kang An
CHM | Chairman | 75 | 92-02-29 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kang An
CHM | Chairman | 75 | 92-02-29 |
Bei Fan
CEO | Chief Executive Officer | 52 | 92-03-29 |
Ruo Wen Pan
BRD | Director/Board Member | 56 | 93-01-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.73% | 4 M€ | -2.96% | ||
| 0.68% | 2 M€ | -16.59% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 18.54 | -2.63% | 25 598 010 |
| 24-04-25 | 19.04 | -0.26% | 9,198,212 |
| 24-04-24 | 19.09 | +0.05% | 6,772,608 |
| 24-04-23 | 19.08 | -0.83% | 12,525,350 |
| 24-04-22 | 19.24 | +1.10% | 11,775,990 |
End-of-day quote Shenzhen S.E., April 25, 2024
More quotes
Hualan Biological Engineering, Inc. specializes in the research, development, manufacturing and marketing of biological and sanguine products and vaccines. The group's products include immunoglobulin for intravenous injections, lyophilized surgical fibrin, lyophilized thrombin for external use, vaccines against cold, etc.
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
18.54
CNY
Average target price
25.78
CNY
Spread / Average Target
+39.07%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.22% | 4.81B | |
| -4.66% | 87.53B | |
| +1.32% | 40.42B | |
| -18.79% | 29.48B | |
| +57.86% | 25.43B | |
| -17.77% | 11.49B | |
| -43.00% | 11.3B | |
| -9.14% | 11.1B | |
| +5.24% | 8.75B | |
| -8.42% | 7.99B |
- Stock Market
- Equities
- 002007 Stock
